Characterization of Absorption, Metabolism, and Elimination of Niraparib, an Investigational Poly (ADP-Ribose) Polymerase Inhibitor, in Cancer Patients
Clinical Therapeutics - United States
doi 10.1016/j.clinthera.2017.05.025
Full Text
Open PDFAbstract
Available in full text
Categories
Date
August 1, 2017
Authors
Publisher
Elsevier BV